Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
- Kisqali
Descriptions
Ribociclib is used in combination with letrozole in patients (women before or after menopause) with hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer. It is also used together with fulvestrant (postmenopausal women) to treat HR-positive, HER-2 negative advanced or metastatic breast cancer.
Ribociclib belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Oct. 01, 2020
Copyright © 2020 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.